100 related articles for article (PubMed ID: 30926633)
1. Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.
Duplaquet L; Figeac M; Leprêtre F; Frandemiche C; Villenet C; Sebda S; Sarafan-Vasseur N; Bénozène M; Vinchent A; Goormachtigh G; Wicquart L; Rousseau N; Beaussire L; Truant S; Michel P; Sabourin JC; Galateau-Sallé F; Copin MC; Zalcman G; De Launoit Y; Fafeur V; Tulasne D
Mol Cancer Ther; 2019 Jun; 18(6):1137-1148. PubMed ID: 30926633
[TBL] [Abstract][Full Text] [Related]
2. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
[TBL] [Abstract][Full Text] [Related]
4. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
[TBL] [Abstract][Full Text] [Related]
5. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
6. Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.
Serizawa M; Kusuhara M; Ohnami S; Nagashima T; Shimoda Y; Ohshima K; Mochizuki T; Urakami K; Yamaguchi K
Anticancer Res; 2016 Jun; 36(6):2733-44. PubMed ID: 27272783
[TBL] [Abstract][Full Text] [Related]
7. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.
Keppler S; Weiβbach S; Langer C; Knop S; Pischimarov J; Kull M; Stühmer T; Steinbrunn T; Bargou R; Einsele H; Rosenwald A; Leich E
Oncotarget; 2016 Jun; 7(25):38762-38774. PubMed ID: 27246973
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
Zhou YQ; He C; Chen YQ; Wang D; Wang MH
Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
[TBL] [Abstract][Full Text] [Related]
11. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
12. Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer.
Oba SM; Wang YJ; Song JP; Li ZY; Kobayashi K; Tsugane S; Hamada GS; Tanaka M; Sugimura H
Cancer Lett; 2001 Mar; 164(1):97-104. PubMed ID: 11166921
[TBL] [Abstract][Full Text] [Related]
13. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
[TBL] [Abstract][Full Text] [Related]
14. Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.
Jauhri M; Bhatnagar A; Gupta S; Shokeen Y; Minhas S; Aggarwal S
Med Oncol; 2016 Oct; 33(10):106. PubMed ID: 27568332
[TBL] [Abstract][Full Text] [Related]
15. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
Wang MH; Lao WF; Wang D; Luo YL; Yao HP
Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinases and their activation in melanoma.
Easty DJ; Gray SG; O'Byrne KJ; O'Donnell D; Bennett DC
Pigment Cell Melanoma Res; 2011 Jun; 24(3):446-61. PubMed ID: 21320293
[TBL] [Abstract][Full Text] [Related]
17. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
18. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
[TBL] [Abstract][Full Text] [Related]
19. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
20. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
